BioSpace News Archive

Inhalon Biopharma today announced initial results from a landmark Phase 1b study that directly compares the distribution and retention of antibodies throughout the human respiratory tract following both inhaled and intravenous (IV) delivery.

HUNTSVILLE, Ala., March 20, 2024 – healthŌme®, Inc., a leading genomics-based, precision health management company serving the life and critical illness industries, and GalenusRx, Inc.,

RespireRx Pharmaceuticals Inc. is pleased to announce that, as part of an ongoing collaboration, a scientist team led by Dr. David Fuller of the University of Florida has published a peer-reviewed research article describing the ability of CX1739.

Kane Biotech Inc. announces today that it has extended the exclusivity period on the offer for its interest in STEM Animal Health that it announced on December 20, 2023, from March 19, 2024 until March 31, 2024.

Antennova, a clinical-stage biotech company focused on oncology today announced completion of the first dosing cohort in the Phase I study for the anti-CD24 antibody, ATN-031 (also known as ATG-031).

Onymos, developer of the world’s first Features-as-a-Service platform, and Vapotherm, Inc. (OTCQX: VAPO), (“Vapotherm”), a global medical technology company whose proprietary high-velocity therapy® products treat patients of all ages suffering from respiratory distress, today announced the formation of a development and commercialization partnership.

Evommune, Inc., a biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, today announced that it has entered into an expanded strategic collaboration with Maruho Co., Ltd., to exclusively develop and commercialize EVO756 in Greater China and additional key Asian countries.

Monogram Orthopaedics Inc. today announced management will host a business update conference call on Thursday, March 21, 2024 at 5:00 p.m.

OKYO Pharma Limited announces that it will be releasing new and comprehensive efficacy data readout from the Phase 2 trial of OK-101 in dry eye disease on March 22, 2024.

Johnson Matthey Plc (JM) announces that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.